One hundred and sixty-seven sufferers with ENKTL who underwent pretreatment 18F-FDG PET/CT have been retrospectively collected. Eighty-four sufferers have been adopted up for at the least 2 years (coaching set = 64, take a look at set = 20). A WSDL technique was developed to allow the integration of the remaining 83 sufferers with incomplete/lacking follow-up data in the coaching set. To take a look at generalization, these knowledge have been derived from three sorts of scanners. Prediction similarity index (PSI) was derived from deep learning options of photographs.
Its discriminative capability was calculated and in contrast with that of a traditional deep learning (CDL) technique. Univariate and multivariate analyses helped discover the significance of PSI and scientific options. PSI achieved space below the curve scores of 0.9858 and 0.9946 (coaching set) and 0.8750 and 0.7344 (take a look at set) in the prediction of progression-free survival (PFS) with the WSDL and CDL strategies, respectively. PSI threshold of 1.Zero might considerably differentiate the prognosis. In the take a look at set, WSDL and CDL achieved prediction sensitivity, specificity, and accuracy of 87.50% and 62.50%, 83.33% and 83.33%, and 85.00% and 75.00%, respectively. Multivariate evaluation confirmed PSI to be an unbiased important predictor of PFS in each the strategies.
Natural killer (NK) cells are recognized to play an essential function in protection towards an infection and tumors. Although there isn’t a clear consensus, most research have proven that the quantity and cytotoxicity of NK cells decreases in end-stage kidney illness (ESKD) sufferers present process hemodialysis. Uremic sufferers chronically undergo from oxidative stress, which could possibly be accountable for downregulation of the activating receptors on NK cells and modulation of ligand expression for activating receptors.
Theoretically, the lowered quantity of NK cells and decreased operate would possibly enhance susceptibility to viral infections and most cancers improvement in sufferers with ESKD. There is rising proof that NK cell numbers could also be an end result predictor in renal transplantation; nonetheless, the scientific significance of NK cell dysfunction in dialysis sufferers requires clarification. In this evaluate, I describe NK cell quantity, cytotoxic exercise, and activating mechanisms in the context of uremia and oxidative stress, which is anticipated to help in elucidating the mechanisms underlying immunodeficiency in dialysis sufferers.
Natural Killer cells and monoclonal antibodies: two companions for profitable antibody dependent cytotoxicity towards tumor cells
Monoclonal antibodies focusing on tumors are one of the most essential discoveries in the area of most cancers. Although a number of efficient antibodies have been developed, a relapse could happen. One of their mechanisms of motion is Antibody Dependent Cell Cytotoxicity (ADCC), by participating the Fc γ receptor CD16 expressing Natural Killer cells, innate lymphoid cells concerned in most cancers immunosurveillance and in a position to kill tumor cells. An absence of NK cells noticed in many cancers could due to this fact be a trigger of the low efficacy of antibodies noticed in some scientific conditions. Here we evaluate clear evidences of the important partnership between NK cells and antibodies confirmed in vitro, in vivo, and in scientific trials in completely different indications, describe the hurdles and methods to boost ADCC and the evolution of monoclonal antibody remedy.
NK cell adoptive immunotherapy mixed with monoclonal antibodies could overcome the resistance to the therapy and improve their efficacy. Adaptive NK cells exhibit a considerably decrease stage of CD38 expression in contrast with standard NK cells, suggesting that they might evade daratumumab-induced fratricide. Moreover, adaptive NK cells exert sturdy daratumumab-mediated effector capabilities ex vivo, together with cytokine manufacturing and degranulation, in contrast with standard NK cells. The composition of adaptive NK cells in BM determines the daratumumab-mediated ex vivo practical exercise of BM NK cells in NDMM sufferers. Unlike standard NK cells, sorted adaptive NK cells from the BM of NDMM sufferers exert substantial cytotoxic exercise towards myeloma cells in the presence of daratumumab.
Antibody mediated activation of natural killer cells in malaria uncovered pregnant girls
Immune effector responses towards Plasmodium falciparum embody antibody-mediated activation of innate immune cells, which might induce Fc effector capabilities, together with antibody-dependent mobile cytotoxicity, and the secretion of cytokines and chemokines. These effector capabilities are regulated by the composition of immunoglobulin G (IgG) Fc N-linked glycans. However, a job for antibody-mediated natural killer (NK) cells activation or Fc N-linked glycans in pregnant girls with malaria has not but been established. Herein, we studied the capability of IgG antibodies from pregnant girls, with placental malaria or non-placental malaria, to induce NK cell activation in response to placental malaria-associated antigens DBL2 and DBL3.
 Alpha-bungarotoxin CF488a |
|||
| 9-00005 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
 Alpha-bungarotoxin, CF568 |
|||
| 9-00006 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin, CF568 |
|||
| 9-00006 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
 Alpha-bungarotoxin, CF594 |
|||
| 9-00007 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
 Alpha-bungarotoxin CF594 |
|||
| 9-00007 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
 Alpha-bungarotoxin, CF633 |
|||
| 9-00009 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin, CF633 |
|||
| 9-00009 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
 Alpha-bungarotoxin |
|||
| 00010-1 | Biotium | 1MG | EUR 168 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
 Fluorescein-Alpha-bungarotoxin |
|||
| 00011 | Biotium | 500uG | EUR 367 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
 Tetramethylrhodamine-Alpha-bungarotoxin |
|||
| 00012 | Biotium | 500uG | EUR 383 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
) Fluorescein-alpha-bungarotoxin: (10x50ug) |
|||
| 00013 | Biotium | 10ST | EUR 417 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
) Tetramethylrhodamine-alpha-bungarotoxin: (10x50ug) |
|||
| 00014 | Biotium | 10ST | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
: (500ug)) Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (500ug) |
|||
| 00015 | Biotium | 500uG | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
: (10x50ug)) Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (10x50ug) |
|||
| 00016 | Biotium | 10ST | EUR 523 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
 Biotin-xx-a-bungarotoxin |
|||
| 00017 | Biotium | 500uG | EUR 433 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
 Alpha-Bungarotoxin, CF555 conjugate |
|||
| 9-00018 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-Bungarotoxin, CF555 conjugate |
|||
| 9-00018 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Biotin-cAMP, diisopropylethylammonium salt: |
|||
| 00020 | Biotium | 1MG | EUR 314 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
) Biotin-cAMP, diisopropylethylammonium salt: (20x50ug) |
|||
| 00020-1 | Biotium | 20ST | EUR 418 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
 Biotin-cGMP, diisopropylethylammonium salt: |
|||
| 00021 | Biotium | 1MG | EUR 344 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
) Biotin-cGMP, diisopropylethylammonium salt: (20x50ug) |
|||
| 00021-1 | Biotium | 20ST | EUR 448 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
 Cyanine 644-cAMP: |
|||
| 00022 | Biotium | 1MG | EUR 491 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
) Cyanine 644-cAMP: (20x50ug) |
|||
| 00022-1 | Biotium | 20ST | EUR 625 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
 Fluorescein Methotrexate, triammonium salt: |
|||
| 00023 | Biotium | 1MG | EUR 281 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
 Staurosporine |
|||
| 00025 | Biotium | 100uG | EUR 139 |
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
 Alpha-bungarotoxin, CF543 |
|||
| 00026 | Biotium | 500uG | EUR 494 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
 Rhodamine phalloidin 300u |
|||
| 00027 | Biotium | 300 | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300 |
|||
 Biotin-xx-phalloidin |
|||
| 00028 | Biotium | 100U | EUR 428 |
|
Description: Minimum order quantity: 1 unit of 100U |
|||
 Fluorescein-phalloidin |
|||
| 00030 | Biotium | 300U | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
 Rhodamine 110 phalloidin |
|||
| 00032 | Biotium | 300ST | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300ST |
|||
 Phalloidin) Sulforhodamine 101 (Texas-Red) Phalloidin |
|||
| 00033 | Biotium | 300EU | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300EU |
|||
 Phalloidin, CF405M |
|||
| 00034 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF405M |
|||
| 00034-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 CF488A-cAMP |
|||
| 00036 | Biotium | 100ug | EUR 172 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 CF640R-cAMP |
|||
| 00037 | Biotium | 100ug | EUR 172 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Phalloidin, CF555 |
|||
| 00040 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF555 |
|||
| 00040-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF647 |
|||
| 00041 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF647 |
|||
| 00041-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF488A |
|||
| 00042 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF488A |
|||
| 00042-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF543 |
|||
| 00043 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF543 |
|||
| 00043-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF568 |
|||
| 00044 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF568 |
|||
| 00044-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF594 |
|||
| 00045 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF594 |
|||
| 00045-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF633 |
|||
| 00046 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF633 |
|||
| 00046-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF660R |
|||
| 00047 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF660R |
|||
| 00047-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF680R |
|||
| 00048 | Biotium | 300U | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF680R |
|||
| 00048-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF350 |
|||
| 00049 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF350 |
|||
| 00049-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF640R |
|||
| 00050 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF640R |
|||
| 00050-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF532 |
|||
| 00051 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF532 |
|||
| 00051-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF660C |
|||
| 00052 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF660C |
|||
| 00052-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF680 |
|||
| 00053 | Biotium | 300U | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF680 |
|||
| 00053-T | Biotium | 50U | EUR 147 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF430 |
|||
| 00054 | Biotium | 300U | EUR 449 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF430 |
|||
| 00054-T | Biotium | 50U | EUR 139 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Phalloidin, CF440 |
|||
| 00055 | Biotium | 300U | EUR 449 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF440 |
|||
| 00055-T | Biotium | 50U | EUR 139 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
 Cholera Toxin Subunit B, CF488A conjugate |
|||
| 00070 | Biotium | 100ug | EUR 261 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF568 conjugate |
|||
| 00071 | Biotium | 100ug | EUR 261 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF594 conjugate |
|||
| 00072 | Biotium | 100ug | EUR 261 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF640R conjugate |
|||
| 00073 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF532 conjugate |
|||
| 00074 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF543 conjugate |
|||
| 00075 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF620R conjugate |
|||
| 00076 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF633 conjugate |
|||
| 00077 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF660R conjugate |
|||
| 00078 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Cholera Toxin Subunit B, CF680R conjugate |
|||
| 00079 | Biotium | 100ug | EUR 282 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
 Human Transferrin, CF488A conjugate |
|||
| 00081 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
 Human Transferrin, CF543 conjugate |
|||
| 00082 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
 Human Transferrin, CF568 conjugate |
|||
| 00083 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
 Human Transferrin, CF594 conjugate |
|||
| 00084 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
 Human Transferrin, CF640R conjugate |
|||
| 00085 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
 Human Transferrin, CF680R conjugate |
|||
| 00086 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
 Human Transferrin, CF750 conjugate |
|||
| 00087 | Biotium | 1mg | EUR 155 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
 HIV-1 tat recombinant antigen |
|||
| 00110-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
|||
HIV-1 tat recombinant antigen |
|||
| 00110-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
|||
 HIV-1 GAG P24 Recombinant Antigen |
|||
| 00111-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
|||
HIV-1 GAG P24 Recombinant Antigen |
|||
| 00111-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
|||
 HIV-1 nef recombinant antigen |
|||
| 00112-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
|||
HIV-1 nef recombinant antigen |
|||
| 00112-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
|||
 HIV-1 env gp41 recombinant antigen |
|||
| 00113-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
|||
HIV-1 env gp41 recombinant antigen |
|||
| 00113-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
|||
 HIV-2 GP 36 Recombinant Antigen |
|||
| 00114-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
|||
HIV-2 GP 36 Recombinant Antigen |
|||
| 00114-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
|||
 HCV core recombinant antigen |
|||
| 00115-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
|||
HCV core recombinant antigen |
|||
| 00115-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
|||
 HCV core recombinant antigen, Biotin conjugate |
|||
| 00115-V-B-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
|||
HCV core recombinant antigen, Biotin conjugate |
|||
| 00115-V-B-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
|||
 HCV core recombinant antigen, FITC conjugate |
|||
| 00115-V-F-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
|||
HCV core recombinant antigen, FITC conjugate |
|||
| 00115-V-F-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
|||
 HCV core recombinant antigen, Rhodamine |
|||
| 00115-V-R-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
|||
HCV core recombinant antigen, Rhodamine |
|||
| 00115-V-R-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
|||
 HCV NS4 recombinant antigen NS4a+b |
|||
| 00116-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
|||
HCV NS4 recombinant antigen NS4a+b |
|||
| 00116-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
|||
 HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
| 00116-V-B-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
| 00116-V-B-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
|||
 HCV NS4 recombinant antigen NS4a+b, FITC |
|||
| 00116-V-F-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, FITC |
|||
| 00116-V-F-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
|||
 HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
| 00116-V-R-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
| 00116-V-R-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
|||
 HCV NS3 recombinant antigen |
|||
| 00117-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
|||
HCV NS3 recombinant antigen |
|||
| 00117-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
|||
 HBV core recombinant antigen |
|||
| 00120-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
|||
HBV core recombinant antigen |
|||
| 00120-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
|||
 HBV core recombinant antigen, Delta |
|||
| 00121-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
|||
HBV core recombinant antigen, Delta |
|||
| 00121-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
|||
 HBV surface recombinant antigen HBsAg |
|||
| 00122-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
|||
HBV surface recombinant antigen HBsAg |
|||
| 00122-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
|||
 HBV surface recombinant antigen HBsAg antigen |
|||
| 00123-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00123-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00124-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00124-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
|||
 ORF2 recombinant antigen) HEV (Birma) ORF2 recombinant antigen |
|||
| 00131-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00131-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00132-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. |
|||
Antibody-mediated NK cell activation was noticed in pregnant girls with malaria, however no variations have been related to susceptibility to placental malaria. Elevated anti-inflammatory glycosylation patterns of IgG antibodies have been noticed in pregnant girls with or with out malaria an infection, which weren’t seen in wholesome non-pregnant controls. This means that pregnancy-associated anti-inflammatory Fc N-linked glycans could dampen the antibody-mediated activation of NK cells in pregnant girls with malaria an infection. Overall, though anti-inflammatory glycans and antibody-dependent NK cell activation have been detected in pregnant girls with malaria, a definitive function for these antibody options in defending towards placental malaria stays to be confirmed.